INTRODUCTION
Transfer factor is a dialyzable, low molecular weight material derived from lysed human leukocytes, which is thought to be capable of transferring cellular immunity from an immune donor to a nonimmune recipient. Basing primarily on the transfer of immunity to histocomThis work was presented in part at the Federation of American Societies for Experimental Biology, Atlantic City, N. J., 9 April 1974.
Received for publication 13 March 1974 and in revised form 14 June 1974. patibility antigens, Lawrence believes that this material transfers the specific immune reactivity of the donor and is a specific informational molecule (1) . However, Bloom (2) has recently reviewed the transfer factor literature and suggested the alternate possibility that transfer factor might act nonspecifically to stimulate the reactivity of a subthreshold number of previously sensitized lymphocytes.
Most clinical studies of transfer factor have utilized the injection of leukocyte lysates or the dialysate of lysed leukocytes (1, (3) (4) (5) (6) . Such crude preparations represent a heterogeneous mixture of small molecular weight compounds. Our laboratory has recently developed a chromatographic technique for isolating the active component of transfer factor (TFc)' which represents approximately 1% by weight of the dialysate and contains all the biological activity of crude transfer factor (7) . The purpose of this study is to determine the activity and specificity of this purified transfer factor preparation using transfer of skin test reactivity with two antigens, tuberculin (PPD), and keyhole limpet hemocyanin (KLH). (8) . All skin tests were applied intradermally in a volume of 0.1 cm3. Two perpendicular diameters of induration were measured 48 h after application of the skin tests, and the average of the two diameters was recorded. Recipients of transfer factor were skin tested at a site remote from transfer factor administration.
METHODS
Transfer factor preparation. Donor leukocytes were collected from donors using an Aminco blood cell separator' and dialyzable transfer factor was prepared by the method of Lawrence (1) . The dialyzed transfer factor was lyophilized and the active component isolated by Sephadex G-25 chromatography as previously described (7) with two modifications. Column size was increased to 100 X 2.5 cm and the separation accomplished in a volatile buffer (0.01 M NH4HCO8, pH 7.8). Fig. 1 illustrates a typical chromatogram and the biologically active component is identified as TF0 to indicate that it is chromatographically isolated transfer factor. TFc adheres to Sephadex and elutes at fivefourths the total bed volume of the column. This characteristic and the use of a volatile buffer allows quantitation of TFc in terms of weight after lyophilization. For this study, TFc was administered as a single subcutaneous injection of 250 jig, the product of approximately 4 X 10' lymphocytes.
Transfer factor donors. Donor 1 was selected because of his strong reactivity to first strength PPD (55 mm). He was immunized with 1 mg KLH and 2 wk later had a 13-mm reaction to a KLH skin test. He also had an 11-mm reaction to SK-SD and negative reactions to mumps, coccidioidin, and candida skin tests. (Table II) . Transfer factor from this donor had also transferred tuberculin Houston, Tex., sensitive to this antigen. An additional index of specificity of transfer would be conversion of skin test reactivity to one of the other antigens used. These antigens are those which a general population may have encountered, and this conversion may represent nonspecific enhancement of a minimal cell-mediated immunity. Among the 10 subjects in group I, there were 28 initially negative skin test reactions to histoplasmin, coccidioidin, trichophyton, or candida. All remained negative after TFc administration with the exception of conversion to a positive coccidioidin skin test (8 mm) in one subject who also had a strongly positive histoplasmin skin test (24 mm) on initial testing. These two antigens are known to have cross-reactivity (9).
DISCUSSION
Many investigators have shown that transfer factor administration alters the cellular immune reactivity of the recipient (5, 7, 10) . The present study once again confirms these findings with transfer of tuberculin reactivity in 15 of 18 recipients and KLH reactivity in 10 of 10 recipients. Lawrence and his coauthors have stated that this transfer is specific for those reactivities possessed by the donor (4, 6) . For this reason, most investigators l select donors with intense skin test reactivity to the antigenic determinant to be transferred, although pools of "normal" transfer factor have been reported to be clinically effective in treating certain immunodeficiency diseases (10) . The question of specificity of transfer and donor selection becomes critical when transfer factor as an immunotherapeutic agent for specific malignancies and infectious diseases is considered. However, the concept that transfer factor transfers only those delayed hypersensitivity reactions possessed by the donor has recently been questioned (2) . Nonspecific effects of transfer factor therapy have been observed in the treatment of immune deficiency diseases (11, 12 (4, 5) . This study demonstrates that in the KLH system, transfer is remarkably efficient with 10 of 10 recipients achieving reactivity (11 mm) to the same skin test dose of KLH as the donor (13 mm). The degree of tuberculin reactivity transferred was again small in comparison to the donors' reactions and conforms to the experience of others. The difference in the intensity of transferred immunity with different antigens may result from intrinsic differences in the antigens themselves. An alternate explanation would be that recent exposure to a particular antigen may increase the amount of specific transfer factor available in circulating leukocytes. This type of phenomenon was suggested by Lawrence, Rapaport, Converse, and Tillet's ability to systemically transfer immunity to histocompatibility antigens only when transfer factor was prepared from a donor at the peak of a fourth set skin graft rejection (6) . The observation that transfer of equivalent degrees of cellular immunity can be accomplished has important implications in the use of transfer factor in immunotherapy regimens and will require studies to delineate the mechanism and factors involved.
